citizensmemorial.com 5 CMH NEWS ALZHEIMER’S DRUG CLINICAL TRIAL UPDATE Patients at the Missouri Memory Center at Citizens Memorial Hospital participated in an international clinical trial with positive results in Alzheimer’s disease (AD) treatment. Pharmaceutical company Eli Lilly and Company (Lilly) is proceeding with global regulatory submissions and has submitted for approval to the U.S. Food and Drug Administration based on the results of this study. In the phase 3 study, donanemab significantly slowed cognitive and functional decline by 35% in patients with early symptomatic AD dementia or mild cognitive impairment due to AD. Results reported by Lilly include: » 47% of participants on donanemab showed no decline based on a key measure of disease severity at one year, compared to 29% of participants on placebo. » Participants on donanemab had 40% less decline in their ability to perform activities of daily living at 18 months. » Participants on donanemab experienced a 39% lower risk of disease progression than participants taking the placebo. Curtis P. Schreiber, M.D., Medical Director of the Missouri Memory Center and CMH Research Department, was the principal investigator on the study in Bolivar, which started in 2021. READ MORE ABOUT THE TRIAL RESULTS at https://bit.ly/44I92qY. CMH is expanding clinical research studies Citizens Memorial Hospital recently created the CMH Research Department to expand clinical research studies at CMH. CMH Neurology and Headache Center and Missouri Memory Center have conducted clinical research studies on Alzheimer’s disease and migraine headaches since 2016 under the direction of Curtis P. Schreiber, M.D. He is a board certified neurologist and headache medicine specialist with more than 20 years of experience in 221 research studies. “We are participating in national clinical trials that are advancing science and leading to new therapies for patients,” says Dr. Schreiber. “By creating the CMH Research Department, we are building on our successes of the past seven years, allowing us to elevate our research efforts even further by soon expanding into additional therapeutic areas.” Clinical research trials provide patients with opportunities to participate in the process of advancing options for medical treatments. Currently, the CMH Research Department is conducting seven Alzheimer’s studies and one migraine study. The department will be starting three additional studies, including two for Alzheimer’s and one for migraine. Plans are to begin offering clinical trials beyond Alzheimer’s and migraine research. Curtis P. Schreiber, M.D., was a featured expert on an international webinar about phase 3 trial results of donanemab. 350 people in 40 countries around the world participated in the webinar. INTERESTED? For more information about the CMH Research Department or current studies, contact Kasie Atchison, Clinical Research Manager, at 417-328-7781 or cmhresearch@citizensmemorial.com. Patients who choose to participate in a clinical trial: » Can be part of the process to advance options for treatment. » Have access to investigational study drugs. » May receive a new treatment for a disease before it is available to the public. » Receive in-depth clinical monitoring throughout the study. » Have access to cuttingedge diagnostic tools.
RkJQdWJsaXNoZXIy ODQ1MTY=